Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00173706
Status:
UNKNOWN
Last Update Posted:
2006-03-01
First Post:
2005-09-12
Brief Title:
Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis
Status:
UNKNOWN
Status Verified Date:
2005-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study designed to test the hypothesis that treatment with L-carnitine will improve the quality of life and some specific symptoms and signs in patients with renal failure submitted to hemodialysis
Detailed Description:
L-Carnitine is a naturally occurring compound that facilitates the transport of fatty acids into mitochondria for beta-oxidation A lack of carnitine in hemodialysis patients is caused by insufficient carnitine synthesis and particularly by the loss through dialytic membranes leading in some patients to carnitine depletion with a relative increase of esterified forms Many studies have shown that L-carnitine supplementation leads to improvements in several complications seen in uremic patients including cardiac complications impaired exercise and functional capacities muscle symptoms increased symptomatic intradialytic hypotension and erythropoietin-resistant anemia normalizing the reduced carnitine palmitoyl transferase activity in red cells
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None